Becton Dickinson reaffirms 2026 guidance after Q2 update, shares with cautious analyst consensus
26.06.2026 - 16:32:11 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 16:31.
Becton Dickinson (US0718131099) reiterated its full-year 2026 revenue guidance after reporting second-quarter 2026 results, with the shares trading on the NYSE under ticker BDX. According to a recent earnings discussion, Q2 revenue reached around 4.7 billion dollars, up roughly 2.6 percent year-on-year, while management maintained a low single-digit growth outlook for the full year. TalkTickers discussion of Becton Dickinson's Q2 2026 earnings
What recent earnings show
The Q2 2026 numbers suggest a modestly expanding top line, with the roughly 4.7 billion dollars in revenue driven by broad-based contributions across healthcare platforms, including biologic drug delivery and advanced monitoring. TalkTickers earnings commentary on Becton Dickinson Management pointed to double-digit growth in several innovation-focused segments, reinforcing the strategy of combining new technology with commercial execution. TalkTickers analysis of segment performance
Analyst view on the BDX shares
On the analyst side, Becton Dickinson currently carries a Hold consensus rating based on 16 Wall Street opinions compiled over the past 12 months, with 7 Buy, 8 Hold and 1 Sell recommendations. MarketBeat overview of Becton Dickinson analyst ratings The aggregated 12-month price target sits near 151 dollars per share, framing expectations for a measured performance of the NYSE-listed S&P 500 healthcare stock. MarketBeat consensus price target data for BDX
Background and price data on Becton Dickinson
More news, data and regulatory filings on the Becton Dickinson shares are available, including historical performance and upcoming events.
The products behind the stock
Becton Dickinson generates its revenue largely from medical technology for hospitals, laboratories and clinics, with core lines including syringes, catheters and infusion systems for drug delivery, diagnostic instruments, and safety-focused devices used in everyday healthcare workflows. Becton Dickinson product and solutions overview
Where the shares trade today
The Becton Dickinson shares (US0718131099) most recently traded on the NYSE at around 151 dollars per share, based on a late-June 2026 consensus snapshot of price targets and fair value indications for BDX. MarketBeat price level information for Becton Dickinson
Key data on the Becton Dickinson shares
- Company: Becton, Dickinson and Company
- ISIN: US0718131099
- WKN: 857675
- Ticker: BDX
- Trading venue: NYSE
- Price (as of 2026-06-25, 15:59): 151.25 USD
- Market cap: around 43 billion USD (as of late June 2026, based on recent share price and shares outstanding)
- Sector / industry: Health Care Equipment & Supplies
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or a solicitation to buy or sell any securities. All data are based on sources believed to be reliable at the time of publication but may change without notice.
